Dual modulation of dopamine release from anterior nucleus accumbens through cholecystokinin-B receptor subsites

Journal of Neurochemistry

Volumn 68, Issue 1, 1997, Pages 162-168

  Léna, Isabelle ^a   Roques, Bernard P ^a   Durieux, Christiane ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

Anterior nucleus accumbens slices; BC 197; BC 264; Cholecystokinin B receptor; Dopamine release; Rat; Subsites

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHOLECYSTOKININ B RECEPTOR; DEVAZEPIDE; DOPAMINE; POTASSIUM ION; RECEPTOR SUBUNIT; TETRODOTOXIN;

ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN SLICE; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; ELECTROPHYSIOLOGY; LIMBIC CORTEX; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ANIMALIA;

EID: 1842403618     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.68010162.x     Document Type: Article

References (48)

1. Benoliel J. J., Mauborgne A., Bourgoin S., Legrand J. C., Hamon M., and Cesselin F. (1992) Opioid control of the in vitro release of cholecystokinin-like material from the rat substantia nigra. J. Neurochem. 58, 916-922.
2. Bock M. G., DiPardo R. M., Evans B. E., Rittle K. E., Whitter W. L., Veber D. E., Anderson P. S., and Freidinger R. M. (1989) Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365, 260. J. Med. Chem. 32, 13-16.
3. Bradwcjn J., Koszycki D., Couëtoux du Tertre A., van Megen H., den Boer J., Westenberg H., and Annable L. (1994) The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch. Gen. Psychiatry 51, 486-493.
4. B receptors in neurons of the brainstem solitary complex of the rat: pharmacological identification. J. Pharmacol. Exp. Ther. 260, 1433-1440.
5. Chang R. S. L. and Lotti V. J. (1986) Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc. Nail. Acad. Sci. USA 83, 4923-4926.
6. Charpentier B., Durieux C., Pélaprat D., Dor A., Reibaud M., Blanchard J.-C., and Roques B. P. (1988a) Enzyme-resistant CCK analogs with high affinities for central receptors. Peptides 9, 835-841.
7. Charpentier B., Pélaprat D., Durieux C., Dor A., Reibaud M., Blanchard J.-C., and Roques B. P. (1988b) Cyclic cholecystokinin analogues with high selectivity for central receptors. Proc. Natl. Acad. Sci. USA 85, 1968-1972.
8. Crawley J. N. (1992) Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. J. Neurosci. 12, 3380-3391.
9. Daugé B., Steimes P., Derrien M., Beau N., Roques B. P., and Féger J. (1989) CCK8 effects on motivational and emotional states of rats involve CCK-A receptors of the posteromedian part of the nucleus accumbens. Pharmacol. Biochem. Behav. 34, 157-163.
10. Daugé V., Böhme G. A., Crawley J. N., Durieux C., Stutzmann J. M., Féger J., Blanchard J. C., and Roques B. P. (1990) Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog, BC 264. Synapse 6, 73-80.
11. Daugé V., Ladurelle N., Derrien M., Durieux C. and Roques B. P. (1993) Potential therapeutic applications of CCK antagonists in anxiety and panic disorders, in Anxiety: Neurobiology, Clinic and Therapeutic Perspectives, Vol. 232 (Hamon M., Ollat H., and Thiébot M. H., eds), pp. 167-176. John Libbey Eurotext Ltd., London.
12. Derrien M., Daugé V., Blommaert B., and Roques B. P. (1994a) The selective CCK-B agonist, BC 264, impairs socially reinforced memory in the three-panel runway test in rats. Behav. Brain Res. 65, 139-146.
13. Derrien M., McCort-Tranchepain I., Ducos B., Roques B. P., and Durieux C. (1994b) Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol Biochem. Behav. 49, 133-141.
14. Durieux C., Coppey M., Zajac J. M., and Roques B. P. (1986) Occurrence of two cholecystokinin binding sites in guinea pig brain cortex. Biochem. Biophys. Res. Commun. 137, 1167-1173.
15. 4 binding sites in mouse and rat brain. Neuropeptides 12, 141-148.
16. Paris P. L., McLaughlin C. L., Baile C. A., Olney J. W., and Komisaruk B. R. (1984) Morphine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin. Science 226, 1215-1217.
17. 3H]pentagastrin. Peptides 4, 755-762.
18. Gaudreau P., Quirion R., St.-Pierre S., Chiueh C. C., and Pert A. (1987) Localization of cholecystokinin receptors in relation to the nigrostriatal and mesolimbic dopaminergic pathways. Neuropeptides 9, 283-293.
19. Harro J., Vasar E., and Bradwejn J. (1993) CCK in animal and human research on anxiety. Trends Pharmacol. Sci. 14, 244-249.
20. Hökfelt T., Rehfeld J. F., Skirboll L., Ivemark B., Goldstein M., and Markey K. (1980) Evidence for coexistence of dopamine and CCK in meso-limbic neurones. Nature 285, 476-478.
21. Huang S. C., Fortune K. P., Wank S. A., Kopin A. S., and Gardner J. D. (1994) Multiple affinity states of different cholecystokinin receptors. J. Biol. Chem. 269, 26121-26126.
22. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D. C., Hunter J. C., Pinnock R. D., and Woodruff G. N. (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA 87, 6728-6732.
23. Imperato A., Honoré T., and Jensen L. H. (1990) Dopamine release in the nucleus caudatus and in the nucleus accumbens is under glutamatergic control through non-NMDA receptors: a study in freely-moving rats. Brain Res. 530, 223-228.
24. Innis R. B. and Snyder S. H. (1980) Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. USA 77, 6917-6921.
25. Itoh S. and Lal H. (1990) Influences of cholecystokinin and analogues on memory processes. Drug Dev. Res. 21, 257-276.
26. 26-33): evidence for CCK-B receptor heterogeneity. J. Pharmacol. Exp. Ther. 255, 1278-1286.
27. Ladurelle N., Keller G., Roques B. P., and Daugé V. (1993) Effects of CCK-8 and of the CCK-B selective agonist BC 264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats. Brain Res. 628, 254-262.
28. Lee Y. M., Beinborn M., McBride E. W., Lu M., Kolakowski L. F. Jr., and Kopin A. S. (1993) The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J. Biol. Chem. 268, 8164-8169.
29. Lemaire M., Piot O., Roques B. P., Böhme G. A., and Blanchard J. C. (1992) Evidence for an endogenous cholecystokininergic balance in social memory. Neuroreport 3, 929-932.
30. Le Moal M. and Simon H. (1991) Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol. Rev. 71, 155-234.
31. Maldonado R., Derrien M., Noble F., and Roques B. P. (1993) Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses. Neuroreport 4, 947-950.
32. Marshall F. H., Barnes S., Hughes J., Woodruff G. N., and Hunter JC (1991) Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. J. Neurochem. 56, 917-922.
33. Migaud M., Roques B. P., and Durieux C. (1994) Effects of cholecystokinin octapeptide and BC 264, a potent and selective CCK-B agonist on aspartate and glutamate release from rat hippocampal slices. Neuropharmacology 33, 737-743.
34. Mogenson G. J., Jones D. L., and Yim C. Y. (1980) From motivation to action: functional interface between limbic system and the motor system. Prog. Neurobiol. 14, 69-97.
35. Moran T. H., Robinson P. H., Goldrich M. S., and McHugh P. R. (1986) Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res. 362, 175-179.
36. Morino P., Mascagni F., McDonald A., and Hökfelt T. (1994) Cholecystokinin corticostriatal pathway in the rat: evidence for bilateral origin from medial prefrontal cortical areas. Neuroscience 59, 939-952.
37. Mueller K. and Whiteside D. A. (1990) Enkephalin prevents CCK-induced enhancement of amphetamine-induced locomotor stereotypy. Brain Res. 513, 119-124.
38. Paxinos G. and Watson C. (1982) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
39. 8. Functional significance of subregional distributions. Neurochem. Int. 10, 495-508.
40. 8 and new related peptides. Ann. NY Acad. Sci. 448, 61-75.
41. Schacter G. B., Yang C. R., Innis N. K., and Mogenson G. J. (1989) The role of the hippocampal-nucleus accumbens pathway in radial-arm maze performance. Brain Res. 494, 339-349.
42. Seamans J. K. and Phillips A. G. (1994) Selective memory impairments produced by transient lidocaine-induced lesions of the nucleus accumbens in rats. Behav. Neurosci. 108, 456-468.
43. Singh L., Lewis A. S., Field M. J., Hughes J., and Woodruff G. N. (1991) Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc. Natl. Acad. Sci. USA 88, 1130-1133.
44. Studier J. M., Reibaud M., Tramu G., Blanc G., Glowinski J., and Tassin J. P. (1984) Pharmacological study on the mixed CCK-8/DA meso-nucleus accumbens pathway: evidence for the existence of storage sites containing the two transmitters. Brain Res. 298, 91-97.
45. Talkad V. D., Patto R. J., Metz D. C., Turner R. J., Fortune K. P., Bhat S. T., and Gardner J. D. (1994) Characterization of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini. Biochim. Biophys. Acta 1224, 103-116.
46. Voigt M., Wang R. Y., and Westfall T. C. (1986) Cholecystokinin octapeptides alter the release of endogenous dopamine from the rat nucleus accumbens in vitro. J. Pharmacol. Exp. Ther. 237, 147-153.
47. Wank S. A., Pisegna J. R., and de Weerth A. (1992) Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc. Natl. Acad. Sci. USA 89, 8691-8695.
48. Youngren K. D., Daly D. A., and Moghaddam B. (1993) Distinct actions of endogenous excitatory amino acids on the outflow of dopamine in the nucleus accumbens. J. Pharmacol. Exp. Ther. 264, 289-293.